Congress

Análisis de minimización de costes de trastuzumab intravenoso frente a trastuzumab subcutáneo para el tratamiento del cáncer de mama metastásico y el cáncer de mama precoz HER2+.

Authors: Gea S, Santiago B, Aceituno S

Year: 2019

Congress: 7 º Congreso de Oncología Médica, Hematología y Farmacia Oncohematológica. Tendiendo puentes


Download PDF
Subscribe to Outcomes´10
Todos los campos marcados con un * son obligatorios
Responsible for the data: Outcomes'10, s.l.u., Purpose: Sending commercial communications. Legitimation: Art. 6.1 Consent of the interested party. Recipient: No data is transferred unless expressly authorised. You may exercise your rights on data protection (access, rectification, opposition, deletion, automated decisions, limitation of treatment, portability) by email at dpo@outcomes10.com. In any case, you can request the protection of the Spanish Data Protection Agency through its website www.aepd.es/. In addition, you can consult more information on the privacy policy
Logo
Aenor gestión de calidad
Aenor seguridad e información
Logotipo
Skip to content